Suchergebnisse - "Infliximab administration & dosage"

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis.

Autoren: Hebeisen, M. Scherer, A. Micheroli, R. et al.

Schlagwörter: Adalimumab/administration & dosage, Adult, Anti-Inflammatory Agents, Non-Steroidal/administration & dosage, Antibodies, Monoclonal/administration & dosage, Antirheumatic Agents/administration & dosage, Etanercept/administration & dosage, Female, Humans, Infliximab/administration & dosage, Male, Middle Aged, Spondylarthritis/drug therapy, Time Factors, Tumor Necrosis Factor Inhibitors/administration & dosage

Dateibeschreibung: application/pdf

Relation: PLoS ONE; https://iris.unil.ch/handle/iris/111063; serval:BIB_3E0804CAE804; 000469425500005

Verfügbarkeit: https://iris.unil.ch/handle/iris/111063
https://doi.org/10.1371/journal.pone.0216746

Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care

Autoren: Christian Enevold Asta Linauskas Claus Henrik Nielsen et al.

Quelle: Glintborg, B, Kringelbach, T, Bolstad, N, Warren, D J, Eng, G, Sørensen, I J, Loft, A G, Hendricks, O, Hansen, I, Linauskas, A, Nordin, H, Kristensen, S, Lindegaard, H, Jensen, D V, Goll, G L, Høgdall, E, Gehin, J, Enevold, C, Nielsen, C H, Krogh, N S, Johansen, J S & Hetland, M L 2018, 'Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care', Scandinavian Journal of Rheumatology, vol. 47, no. 5, pp. 418–421. https://doi.org/10.1080/03009742.2017.1376110
Glintborg, B, Kringelbach, T, Bolstad, N, Warren, D J, Eng, G, Sørensen, I J, Loft, A G, Hendricks, O, Hansen, I, Linauskas, A, Nordin, H, Kristensen, S, Lindegaard, H, Jensen, D V, Goll, G L, Høgdall, E, Gehin, J, Enevold, C, Nielsen, C H, Krogh, N S, Johansen, J S & Hetland, M L 2018, ' Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care ', Scandinavian Journal of Rheumatology, vol. 47, no. 5, pp. 418-421 . https://doi.org/10.1080/03009742.2017.1376110
Glintborg, B, Kringelbach, T, Bolstad, N, Warren, D J, Eng, G, Sørensen, I J, Loft, A G, Hendricks, O, Hansen, I, Linauskas, A, Nordin, H, Kristensen, S, Lindegaard, H, Jensen, D V, Goll, G L, Høgdall, E, Gehin, J, Enevold, C, Nielsen, C H, Krogh, N S, Johansen, J S & Hetland, M L 2018, 'Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care', Scandinavian Journal of Rheumatology, vol. 47, no. 5, pp. 418-421. https://doi.org/10.1080/03009742.2017.1376110

Schlagwörter: Adult, Male, Arthritis/blood, Arthritis, Denmark, Monoclonal/blood, Antibodies, Monoclonal, Antibodies/blood, Middle Aged, Antibodies, Infliximab, 3. Good health, Antibodies, Monoclonal/blood, 03 medical and health sciences, 0302 clinical medicine, Humans, Female, Infliximab/administration & dosage, Aged, Follow-Up Studies

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/29310493
https://vbn.aau.dk/da/publications/drug-concentrations-and-anti-drug-antibodies-during-treatment-wit
https://www.tandfonline.com/doi/abs/10.1080/03009742.2017.1376110
https://core.ac.uk/display/146822811
https://www.tandfonline.com/doi/pdf/10.1080/03009742.2017.1376110
http://europepmc.org/abstract/MED/29310493
https://portal.findresearcher.sdu.dk/da/publications/drug-concentrations-and-anti-drug-antibodies-during-treatment-wit
https://portal.findresearcher.sdu.dk/da/publications/7c9ea69d-1e62-409e-beae-95c15888b00f

Association of IgG1 Antibody Clearance with FcγRIIA Polymorphism and Platelet Count in Infliximab-Treated Patients.

Autoren: Thibault, Gilles Paintaud, Gilles Sung, Hsueh Cheng et al.

Quelle: International Journal of Molecular Sciences, 22 (11) (2021)

Schlagwörter: Adult, Antigen-Antibody Complex/genetics/immunology, Blood Platelets/drug effects/immunology, Crohn Disease/blood/drug therapy/genetics/immunology, Endothelial Cells/drug effects/immunology, Female, Flow Cytometry, Humans, Immunoglobulin G/genetics/immunology, Infliximab/administration & dosage/pharmacokinetics, Male, Platelet Activation/drug effects, Platelet Count, Polymorphism, Genetic/genetics, Receptors, IgG/genetics, FcγRIIA, Fc–Fc receptor interaction, IgG subclasses, clearance, immunotherapy, monoclonal antibodies, platelets, Human health sciences, Gastroenterology & hepatology, Sciences de la santé humaine, Gastroentérologie & hépatologie

Relation: https://doi.org/10.3390/ijms22116051; urn:issn:1661-6596; urn:issn:1422-0067; https://orbi.uliege.be/handle/2268/266126; info:hdl:2268/266126; info:pmid:34205175

Verfügbarkeit: https://orbi.uliege.be/handle/2268/266126
https://orbi.uliege.be/bitstream/2268/266126/1/Association%20of%20IgG1%20Antibody%20Clearance%20with%20Fc%ce%b3RIIA%20Polymorphism%20and%20Platelet%20Count%20in%20Infliximab-Treated%20Patients_IntJMolSci_PPE.pdf
https://doi.org/10.3390/ijms22116051

Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis

Autoren: Loft, N D Skov, L Iversen, L et al.

Quelle: Loft, N D, Skov, L, Iversen, L, Gniadecki, R, Dam, T N, Brandslund, I, Hoffmann, H J, Andersen, M R, Dessau, R B, Bergmann, A C, Andersen, N M, Andersen, P S, Bank, S, Vogel, U & Andersen, V 2018, ' Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis ', Pharmacogenomics Journal, vol. 18, pp. 494-500 . https://doi.org/10.1038/tpj.2017.31
Loft, N D, Skov, L, Iversen, L, Gniadecki, R, Dam, T N, Brandslund, I, Hoffmann, H J, Andersen, M R, Dessau, R B, Bergmann, A C, Møller Andersen, N, Andersen, P S, Bank, S, Vogel, U & Andersen, V 2018, ' Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis ', Pharmacogenomics Journal, vol. 18, no. 3, pp. 494–500 . https://doi.org/10.1038/tpj.2017.31
Loft, N D, Skov, L, Iversen, L, Gniadecki, R, Dam, T N, Brandslund, I, Hoffmann, H J, Andersen, M R, Dessau, R B, Bergmann, A C, Andersen, N M, Andersen, P S, Bank, S, Vogel, U & Andersen, V 2018, 'Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis', Pharmacogenomics Journal, vol. 18, no. 3, pp. 494-500. https://doi.org/10.1038/tpj.2017.31

Schlagwörter: Male, PROMOTER, PREDICTION, Denmark, Interleukin-1beta, Etanercept, 0302 clinical medicine, Receptors, Pharmacogenetics/methods, Receptors, Interleukin-1/genetics, Membrane Glycoproteins, ANTI-TNF-ALPHA, Single Nucleotide, Middle Aged, 3. Good health, Ustekinumab/administration & dosage, ALLELE, Treatment Outcome, Female, Interleukin-1beta/genetics, Adult, USTEKINUMAB, Lymphocyte Antigen 96, GENE POLYMORPHISMS, Polymorphism, Single Nucleotide, Toll-Like Receptor 2/genetics, 03 medical and health sciences, VARIANTS AFFECT, Psoriasis/drug therapy, Humans, Psoriasis, Polymorphism, Etanercept/administration & dosage, TOLL-LIKE RECEPTORS, Toll-Like Receptor 9/genetics, INTERFERON-GAMMA, Tumor Necrosis Factor-alpha/antagonists & inhibitors, Tumor Necrosis Factor-alpha, CLINICAL-RESPONSE, Adalimumab, Receptors, Interleukin-1, Adalimumab/administration & dosage, Membrane Glycoproteins/genetics, Interleukin-1/genetics, Infliximab, Toll-Like Receptor 2, Pharmacogenetics, Toll-Like Receptor 9, Infliximab/administration & dosage, Lymphocyte Antigen 96/genetics

Dateibeschreibung: application/pdf

Zugangs-URL: https://www.nature.com/articles/tpj201731.pdf
https://pubmed.ncbi.nlm.nih.gov/28696418
https://portal.findresearcher.sdu.dk/da/publications/associations-between-functional-polymorphisms-and-response-to-bio
https://europepmc.org/article/MED/28696418
https://www.nature.com/articles/tpj201731.pdf
https://www.nature.com/articles/tpj201731
https://findresearcher.sdu.dk:8443/ws/files/141052037/Associations_between_functional_polymorphisms_and_response_to_biological_treatment_in_Danish_patients_with_psoriasis.pdf
https://www.ncbi.nlm.nih.gov/pubmed/28696418
https://curis.ku.dk/ws/files/197765027/tpj201731.pdf
https://portal.findresearcher.sdu.dk/da/publications/58c50b51-bbde-4373-bfaf-47f0622041da
https://doi.org/10.1038/tpj.2017.31
https://findresearcher.sdu.dk:8443/ws/files/141052037/Associations_between_functional_polymorphisms_and_response_to_biological_treatment_in_Danish_patients_with_psoriasis.pdf
https://pure.au.dk/portal/en/publications/e1c2cffd-95fe-40a3-9172-63fd9d62d37f
https://doi.org/10.1038/tpj.2017.31

A boy in his teens with large ulcerations of the head and neck / Gutt i tenårene med store ulcerasjoner i hodet og nakken

Autoren: Moen, Björnar Halsör Nystad, Tone Wikene Barrett, Torill Myklestad et al.

Quelle: Tidsskrift for Den Norske Laegeforening. 139(7):624

Long‐term therapy with anakinra in hidradenitis suppurativa in three patients

Autoren: Andre, Raphaël Marescassier, Hélène Gabay, Cem et al.

Quelle: International Journal of Dermatology, Vol. 58, No 11 (2019) pp. e208-e209

Schlagwörter: Infliximab / administration & dosage, 03 medical and health sciences, 0302 clinical medicine, ddc:617, Drug Substitution, Hidradenitis Suppurativa

Dateibeschreibung: application/pdf

Zugangs-URL: https://europepmc.org/article/MED/31353451
https://archive-ouverte.unige.ch/unige:134026
https://onlinelibrary.wiley.com/doi/full/10.1111/ijd.14596
https://www.ncbi.nlm.nih.gov/pubmed/31353451
https://archive-ouverte.unige.ch/unige:134026

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.

Autoren: D'Haens, Geert Vermeire, Severine Lambrecht, Guy et al.

Quelle: Gastroenterology, 154 (5), 1343-1351.e1 (2018)

Schlagwörter: Adrenal Cortex Hormones/administration & dosage/adverse effects, Adult, Anti-Inflammatory Agents/administration & dosage/adverse effects/blood, Biomarkers/blood, Crohn Disease/blood/diagnosis/drug therapy/immunology, Double-Blind Method, Drug Dosage Calculations, Drug Monitoring, Drug Therapy, Combination, Endoscopy, Gastrointestinal, Europe, Female, Gastrointestinal Agents/administration & dosage/adverse effects/blood, Humans, Infliximab/administration & dosage/adverse effects/blood, Male, Predictive Value of Tests, Proof of Concept Study, Prospective Studies, Remission Induction, Time Factors, Treatment Outcome, Young Adult, Crohn's Disease, Infliximab, Mucosal Healing, Therapeutic Drug Monitoring, Human health sciences

Relation: http://www.elsevier.com; urn:issn:0016-5085; urn:issn:1528-0012; https://orbi.uliege.be/handle/2268/234438; info:hdl:2268/234438; https://orbi.uliege.be/bitstream/2268/234438/1/Increasing%20Infliximab%20dose%20based%20on%20symptoms%2c%20biomarkers%2c%20and%20serum%20drug%20concentrations%20does%20not.Crohn%20s%20disease_Gastrent_PPA_EL.doc; info:pmid:29317275

Verfügbarkeit: https://orbi.uliege.be/handle/2268/234438
https://orbi.uliege.be/bitstream/2268/234438/1/Increasing%20Infliximab%20dose%20based%20on%20symptoms%2c%20biomarkers%2c%20and%20serum%20drug%20concentrations%20does%20not.Crohn%20s%20disease_Gastrent_PPA_EL.doc
https://doi.org/10.1053/j.gastro.2018.01.004

Individualizing biological therapies / Persontilpasset behandling med biologiske legemidler

Autoren: Bergan, Stein Bolstad, Nils

Quelle: Norsk Farmaceutisk Tidsskrift. 126(1):40

Parkinsonism as a side effect of infliximab

Autoren: Henriksen, Jakob Nørgaard Eriksson, Bengt Oluf Mikael

Quelle: Henriksen, J N & Eriksson, B O M 2016, 'Parkinsonism as a side effect of infliximab', BMJ Case Reports, vol. 2016, 214802. https://doi.org/10.1136/bcr-2016-214802

Schlagwörter: 0301 basic medicine, Middle Aged, Infliximab, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Parkinsonian Disorders/chemically induced, Crohn Disease, Parkinsonian Disorders, 13. Climate action, Crohn Disease/drug therapy, Humans, Female, Infliximab/administration & dosage

Zugangs-URL: https://europepmc.org/articles/pmc4885252?pdf=render
https://pubmed.ncbi.nlm.nih.gov/27151053
http://europepmc.org/articles/PMC4885252
https://casereports.bmj.com/content/2016/bcr-2016-214802
https://casereports.bmj.com/lookup/doi/10.1136/bcr-2016-214802
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885252
https://casereports.bmj.com/content/casereports/2016/bcr-2016-214802.full.pdf
https://casereports.bmj.com/content/2016/bcr-2016-214802.full.pdf

Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care

Autoren: Glintborg, B Kringelbach, T Bolstad, N et al.

Quelle: Glintborg , B , Kringelbach , T , Bolstad , N , Warren , D J , Eng , G , Sørensen , I J , Loft , A G , Hendricks , O , Hansen , I , Linauskas , A , Nordin , H , Kristensen , S , Lindegaard , H , Jensen , D V , Goll , G L , Høgdall , E , Gehin , J , Enevold , C , Nielsen , C H , Krogh , N S , Johansen , J S & Hetland , M L 2018 , ' Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care ' , Scandinavian Journal of Rheumatology , vol. 47 , no. 5 , pp. 418-421 .

Index Begriffe: Adult, Aged, Antibodies/blood, Antibodies, Monoclonal/blood, Arthritis/blood, Denmark, Female, Follow-Up Studies, Humans, Infliximab/administration & dosage, Male, Middle Aged, article

URL: https://researchprofiles.ku.dk/da/publications/drug-concentrations-and-antidrug-antibodies-during-treatment-with-biosimilar-infliximab-ctp13-in-routine-care(a05b3494-6fb6-4779-af82-2bfed56a47ff).html
https://doi.org/10.1080/03009742.2017.1376110